Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

Autor: Reck, Martin, Schenker, Michael, Lee, Ki Hyeong, Provencio, Mariano, Nishio, Makoto, Lesniewski-Kmak, Krzysztof, Sangha, Randeep, Ahmed, Samreen, Raimbourg, Judith, Feeney, Kynan, Corre, Romain, Franke, Fabio Andre, Richardet, Eduardo, Penrod, John R., Yuan, Yong, Nathan, Faith E., Bhagavatheeswaran, Prabhu, DeRosa, Michael, Taylor, Fiona, Lawrance, Rachael, Brahmer, Julie

Publikováno v: In European Journal of Cancer July 2019 116:137-147

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer

Autor: Hellmann, Matthew, Paz-Ares, Luis, Bernabe Caro, Reyes, Zurawski, Bogdan, Kim, Sang-We, Carcereny Costa, Enric, Park, Keunchil, Alexandru, Aurelia, Lupinacci, Lorena, de La Mora Jimenez, Emmanuel, Sakai, Hiroshi, Albert, Istvan, Vergnenègre, Alain, Peters, Solange, Syrigos, Konstantinos, Barlesi, Fabrice, Reck, Martin, Borghaei, Hossein, Brahmer, Julie, O'Byrne, Kenneth, Geese, William, Bhagavatheeswaran, Prabhu, Rabindran, Sridhar, Kasinathan, Ravi, Nathan, Faith, Ramalingam, Suresh, O’byrne, Kenneth

Publikováno v: New England Journal of Medicine
r-IGTP: Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Institut de Recerca Germans Trias i Pujol (IGTP)
New England Journal of Medicine, 2019, 381 (21), pp.2020-2031. ⟨10.1056/NEJMoa1910231⟩
Digital.CSIC. Repositorio Institucional del CSIC
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
New England Journal of Medicine, Massachusetts Medical Society, 2019, 381 (21), pp.2020-2031. ⟨10.1056/NEJMoa1910231⟩

[Background] In an early-phase study involving patients with advanced non–small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18ad09d5c956f063b752bce70429dbbb
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1330

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer

Autor: CheckMate 026 Investigators, Carbone, David P, Reck, Martin, Paz-Ares, Luis, Creelan, Benjamin, Horn, Leora, Steins, Martin, Felip, Enriqueta, van den Heuvel, Michel M, Ciuleanu, Tudor-Eliade, Badin, Firas, Ready, Neal, Hiltermann, T Jeroen N, Nair, Suresh, Juergens, Rosalyn, Peters, Solange, Minenza, Elisa, Wrangle, John M, Rodriguez-Abreu, Delvys, Borghaei, Hossein, Blumenschein, George R, Villaruz, Liza C, Havel, Libor, Krejci, Jana, Corral Jaime, Jesus, Chang, Han, Geese, William J, Bhagavatheeswaran, Prabhu, Chen, Allen C, Socinski, Mark A

Publikováno v: The New England journal of medicine, vol. 376, no. 25, pp. 2415-2426
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
The New England Journal of Medicine, 376, 2415-2426
The New England Journal of Medicine, 376, 25, pp. 2415-2426
The New England journal of medicine
New England Journal of Medicine, 376(25), 2415-2426. MASSACHUSETTS MEDICAL SOC

BACKGROUNDNivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non-small-cell lung cancer (NSCLC). In an open-label phase 3 trial, we compared first-line nivolumab with chemotherapy in patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c46efbf8f587b0fe0e715459df71477c
https://serval.unil.ch/resource/serval:BIB_5A4A2E2F4748.P001/REF.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.